SAFE Drugs Act of 2025
U.S. Congress · HR6509 ·
Progression
Timing in context
Primary sponsor's contributions received (same period)
Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.
What the bill says
Introduced 2025-12-09. Latest action: Referred to the House Committee on Energy and Commerce.
Summary (plain-language)
Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2025 or the SAFE Drugs Act of 2025 This bill provides for increased oversight of drug compounding and imposes statutory limits on compounded drugs that are essentially copies of commercially available drugs. Currently, subject to certain requirements, compounded drugs (i.e., drugs that are mixed or altered to meet patient needs) do not require Food and Drug Administration (FDA) approval. Additional limits apply to the compounding of drugs that are essentially copies of commercially available drug products. Under the bill, a compounded drug is essentially a copy of a commercially available drug product if (1) the compounded drug contains any active ingredient found in a commercially available drug product, and (2) there is no change made for an individual patient that results in a significant difference between the compounded drug and the commercially available drug. (The FDA’s current definition of the term also addresses dosage strength and route of administration.) The bill increases the frequency at which a licensed pharmacist or physician may compound a drug that is essentially a copy of a commercially available drug to 20 times per month. Current FDA policy allows four such prescriptions per month. The bill also imposes annual reporting requirements on physicians, facilities, and pharmacies (except hospital-based pharmacies) that compound certain drug products for out-of-state patients more than 20 times per month. Further, the bill subjects certain large-scale outsourcing facilities (i.e., FDA-registered facilities that compound in bulk) to regular inspection and reporting requirements.
Sponsors
- Rudy Yakym III (primary)
- James R. Baird
- Aaron Bean
- André Carson
- Donald G. Davis
- Chuck Edwards
- Vince Fong
- Erin Houchin
- Mike Kelly
- Carol D. Miller
- Frank J. Mrvan
- Nathaniel Moran
- Mark B. Messmer
- John J. McGuire III
- Addison P. McDowell
- Deborah K. Ross
- Marlin A. Stutzman
- Jefferson Shreve
- Claudia Tenney
- Eugene Simon Vindman
Text versions
- Introduced in House — 2025-12-09 — XML
What analysts say
No nonpartisan analysis on file for this measure yet.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2025-12-09 | Introduced in House |
| 2025-12-09 | Referred to the House Committee on Energy and Commerce. |